Summit Hotel Properties, Inc. (INN-PE)
| Previous Close | 21.24 |
| Open | 21.03 |
| Bid | 21.05 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 20.98 - 21.24 |
| 52 Week Range | 17.03 - 22.48 |
| Volume | |
| Avg. Volume | 10,046 |
| Market Cap | 1.008B |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.56 (7.45%) |
| Ex-Dividend Date | Feb 14, 2024 |
| 1y Target Est | N/A |
CNW GroupInnocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
- CNW Group
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2023.
PR NewswireSUMMIT HOTEL PROPERTIES ANNOUNCES FIRST QUARTER 2024 EARNINGS RELEASE DATE
Summit Hotel Properties, Inc. (NYSE: INN) (the "Company") today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 1, 2024, after the market closes.
